Guillen OFC, Díaz BA

Language: Spanish
References: 8
Page: 251-254
PDF size: 546.13 Kb.

ABSTRACT

Introduction: venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is influenced by hereditary and acquired risk factors. Among the acquired factors, obesity, advanced age, and acute illnesses requiring hospitalization increase the predisposition to VTE. In patients with acute non-surgical medical conditions, thromboprophylaxis is underutilized, despite the existence of the internationally validated Padua scale, which assesses VTE risk and guides the implementation of mechanical or pharmacological prophylaxis. Objective: to determine the percentage of non-surgical patients at Hospital Angeles Lomas, at high risk of VTE according to the Padua scale, who received thromboprophylaxis. Material and methods: observational, cross-sectional, and retrospective study. Patients hospitalized for more than 48 hours due to acute non-surgical medical conditions between October 2022 and March 2023 were included. A non-probabilistic sampling method was used, and medical records were reviewed. A Padua score › 4 indicated high VTE risk, and prophylaxis administration was assessed. Results: of 214 patients, 28.9% had a Padua score › 4, of whom 96.77% received thromboprophylaxis. Conclusions: patients at high risk of venous thromboembolism according to the Padua score received thromboprophylaxis at a high percentage (96.77%). These results reflect adequate adherence to prophylaxis recommendations in this population.

REFERENCES

1. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep veinthrombosis. N Engl J Med. 2019; 380 (12): 1139-1149.

2. Spyropoulos AC, Ageno W, Cohen AT, Gibson CM, Goldhaber SZ,Raskob G. Prevention of venous thromboembolism in hospitalizedmedically ill patients: a U.S. perspective. Thromb Haemost. 2020;120 (6): 924-936.

3. Cabrera-Rayo A, Nellen-Hummel H. Epidemiología de la enfermedadtromboembólica venosa. Gac Med Mex. 2007; 143 (Suppl: 1): 3-5.

4. Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK,Deslandes B et al. Venous thromboembolism risk and prophylaxisin the acute hospital care setting (ENDORSE study): a multinationalcross-sectional study. Lancet. 2008; 371 (9610): 387-394.

5. Schünemann HJ, Cushman M, Burnett AE et al. American Societyof Hematology 2018 guidelines for management of venousthromboembolism: prophylaxis for hospitalized and nonhospitalizedmedical patients. Blood Adv. 2018; 2 (22): 3198-3225. Blood Adv.2023; 7 (9): 1671.

6. Cabrera-Rayo A, Hernández-Díaz EJ, Guzmán-Rosales G, Laguna-Hernández G, Pliego-Reyes C, Zendejas-Villanueva JL et al.Tromboprofilaxis en pacientes médicos y quirúrgicos: resultados deun estudio multicéntrico realizado en hospitales de la Ciudad deMéxico. Med Int Méx. 2017; 33 (6): 746-753. doi: 10.24245/mim.v33i6.1461.

7. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M et al.A risk assessment model for the identification of hospitalized medicalpatients at risk for venous thromboembolism: the Padua PredictionScore. J Thromb Haemost. 2010; 8 (11): 2450-2457.

8. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, DrigginE et al. COVID-19 and thrombotic or thromboembolic disease:implications for prevention, antithrombotic therapy, and followup:JACC state-of-the-art review. J Am Coll Cardiol. 2020; 75 (23):2950-2973.